SURFACE LOGIX INC. TO PRESENT AT THE 2006 BIO INVESTOR FORUM

BOSTON, Mass. (October 17, 2006) – Surface Logix Inc. announced that Jim Mahoney, President and Chief Executive Officer, will present an update of the company’s drug development pipeline at the 2006 BIO Investor Forum on October 19, 2006 at 10:20 a.m. Pacific (1:20 p.m. Eastern) time from The Palace Hotel in San Francisco.

Surface Logix Inc currently has two programs in human clinical trials with a third program approaching its initial regulatory submission. Mr. Mahoney will discuss the latest results for SLx-2101, currently in Phase 1Ia, a second generation PDE5 inhibitor, designed to address cardiovascular indications including Raynaud’s Syndrome and Hypertension; and, SLx-4090, soon to be in Phase 1Ia, a first in class enterocyte specific MTP inhibitor targeting unmet needs in dyslipidemia and metabolic disorders.

About Surface Logix Inc.

Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.

Contact:
David H. Donabedian, Ph.D.
Vice President, Business Development
617.746.8520

Media:
Kari Watson
MacDougall Biomedical Communications Inc.
508.647.0209